BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Head and Neck Squamous Cell Carcinoma readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Head and Neck Squamou
 s Cell Carcinoma\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06668961-2265@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Izalontamab: Phase 2 readout est. (NCT06668961)
DESCRIPTION:Izalontamab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Study of SI-B001+SI-B003 Combined With Platinum-based Chemothera
 py as First-line Treatment in Patients With Recurrent or Metastatic Head a
 nd Neck Squamous Cell Carcinoma\nEstimated primary completion: November 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/izalontamab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06668961
URL:https://assetmemo.bio/drug/izalontamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955290-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT02955290)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  CIMAvax Vaccine\, Nivolumab\, and Pembrolizumab in Treating Patients With
  Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer\nEst
 imated primary completion: 25 November 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02955290
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955290-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT02955290)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: CIM
 Avax Vaccine\, Nivolumab\, and Pembrolizumab in Treating Patients With Adv
 anced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer\nEstimat
 ed primary completion: 25 November 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02955290
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05668858-2265@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab: Phase 1/2 readout est. (NCT05668858)
DESCRIPTION:Izalontamab\, phase 1/2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study of SI-B001+SI-B003± Chemotherapy in Patients With Local
 ly Advanced or Metastatic Head and Neck Squamous Cell Carcinoma\nEstimated
  primary completion: December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/izalontamab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05668858
URL:https://assetmemo.bio/drug/izalontamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943820-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT06943820)
DESCRIPTION:Cetuximab\, phase 1/2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: AK129 Combination Therapy for Advanced Solid Tumors\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06943820
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05784688-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05784688)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Colorectal Cancer.\nStudy: Study of
  TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Adv
 anced Solid Tumors\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05784688
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943820-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT06943820)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: AK129 Combination Therapy for Advanced Solid Tumors\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06943820
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05977907-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05977907)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcin
 oma of the Head and Neck (SCCHN).\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05977
 907
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06580054-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06580054)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Pembrolizumab for the Treatment of Locally Advanced and/or Recur
 rent Orbital or Periocular Cutaneous Squamous Cell Carcinoma\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06580054
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05054439-2265@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Izalontamab: Phase 2 readout est. (NCT05054439)
DESCRIPTION:Izalontamab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetax
 el in the Treatment of Recurrent and Metastatic HNSCC\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/izalontamab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05054439
URL:https://assetmemo.bio/drug/izalontamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05054439-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05054439)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: A Clinical Study of SI-B001 in Combination With Paclitaxe
 l/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC\nEstimated 
 primary completion: December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05054439
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04375384-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT04375384)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Cetuximab After Immunotherapy for the Treatment of Head and Neck Squ
 amous Cell Cancer\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04375384
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05420948-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05420948)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study of Pembrolizumab in Combination With Chemotherapy for He
 ad and Neck Cancer\nEstimated primary completion: 1 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05420948
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06161545-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06161545)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK 
 Cells for Resectable Head and Neck Squamous Cell Carcinoma\nEstimated prim
 ary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06161545
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998069-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Cetuximab: Phase 3 readout est. (NCT06998069)
DESCRIPTION:Cetuximab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Head and Neck Cancer Study Project in the Geriatric Population\nEsti
 mated primary completion: 1 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06998069
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06998069-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06998069)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Head and Neck Cancer Study Project in the Geriatric Population\n
 Estimated primary completion: 1 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06998069
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585750-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04585750)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harborin
 g a TP53 Y220C Mutation (PYNNACLE)\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4585750
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06793761-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06793761)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Phase II Study to Evaluate the Efficacy and Safety of Salvage 
 Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy
  in Recurrent and Metastatic LPSCC/HPSCC\nEstimated primary completion: 20
  December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembr
 olizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06793761
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04180371-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04180371)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2
  Expression\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04180371
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136545-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07136545)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Head and Neck Squamous Cell Carcino
 ma.\nStudy: A Phase I/II Trial of HCB101 in Combination With Pembrolizumab
  for Patients With Platinum-Refractory\, Recurrent or Metastatic Head and 
 Neck Squamous Cell Carcinoma (SirH&N Trial)\nEstimated primary completion:
  31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07136545
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03383094-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03383094)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Chemoradiation vs Immunotherapy and Radiation for Head and Neck 
 Cancer\nEstimated primary completion: 31 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03383094
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06239220-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06239220)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: PD-L1 t-haNK\, NAI IL-15sa and Cetuximab for Recurrent\, Metastatic 
 HNSCC\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06239220
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06052839-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06052839)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metasta
 tic HNSCC\nEstimated primary completion: 31 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06052839
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05280457-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05280457)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients
  With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination\
 , GX-I7 and Nivolumab Combination Therapy\nEstimated primary completion: J
 anuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivoluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 280457
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05136196-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05136196)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivo
 lumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and 
 Neck Cancer\, an immunoMATCH Pilot Study\nEstimated primary completion: 1 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5136196
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04938609-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270111
DTEND;VALUE=DATE:20270112
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04938609)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC
 )\nEstimated primary completion: 11 January 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04938609
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05366166-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05366166)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Pembrolizumab Plus Olaparib in LA-HNSCC\nEstimated primary compl
 etion: 21 January 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05366166
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06549946-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06549946)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Head and Neck Squamous Cell Carcino
 ma.\nStudy: Ixovex-1 Single Agent and Combination Therapy\nEstimated prima
 ry completion: 30 January 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06549946
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, G
 lioblastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion
 : 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 embrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06047379
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Saf
 ety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gliob
 lastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivol
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06047379
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059221-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT07059221)
DESCRIPTION:Cetuximab\, phase 1/2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-t
 umor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinom
 a Cancer\nEstimated primary completion: March 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07059221
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04848116-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04848116)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Neoadjuvant Targeting of Myeloid Cell Populations in Combination Wit
 h Nivolumab in Head & Neck Ca\nEstimated primary completion: April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04848116
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06102395-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06102395)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Evaluating the Efficacy and Safety of Pembrolizumab Plus Standar
 d Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC\n
 Estimated primary completion: 30 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06102395
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06102395-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Taxotere (Docetaxel): Phase 3 readout est. (NCT06102395)
DESCRIPTION:Taxotere (Docetaxel)\, phase 3\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: Evaluating the Efficacy and Safety of Pembrolizumab Plus 
 Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) 
 HNSCC\nEstimated primary completion: 30 April 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06102395
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05358548-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05358548)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: ATATcH Alternating Treatment Plans for Advanced Cancer\nEstimate
 d primary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05358548
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265285-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06265285)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Compa
 rison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab
  Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls 
 (CCBW) Program\nEstimated primary completion: 1 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265285
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04831320-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04831320)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or M
 etastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 
 or PD-L1 Inhibitor\nEstimated primary completion: 30 June 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04831320
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03546582-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03546582)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurre
 nt or Second Primary Head and Neck Carcinoma\nEstimated primary completion
 : July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroli
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT03546582
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03576417-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03576417)
DESCRIPTION:Nivolumab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Tre
 atment of Cancers of the Head and Neck\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT035764
 17
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06869473-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270820
DTEND;VALUE=DATE:20270821
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06869473)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Cetuximab Plus Platinum and Taxane-based Chemotherapy\, Followed by 
 Avelumab and Cetuximab\, as First-line Treatment for Recurrent/Metastatic 
 Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combin
 ed Positive Score (CPS)≥1≤19.\nEstimated primary completion: 20 August
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06869473
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06640725-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271002
DTEND;VALUE=DATE:20271003
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06640725)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab 
 in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N\n
 Estimated primary completion: 2 October 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06640725
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03406247-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03406247)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamo
 us Cell Carcinoma\nEstimated primary completion: November 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03406247
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03556228-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03556228)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA O
 verexpression Driven Solid Tumors or Lymphoma\nEstimated primary completio
 n: December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT03556228
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06694350-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06694350)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Pembrolizumab in Combination with Flutamide Treatment for Recurr
 ence / Metastasis HNSCC\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06694350
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910827-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Cetuximab: Phase 1/2 readout est. (NCT05910827)
DESCRIPTION:Cetuximab\, phase 1/2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Phase Ib/II Study of an Anti-HER3 Antibody\, HMBD-001\, With Cet
 uximab +/- Docetaxel in Advanced Squamous Cell Cancers\nEstimated primary 
 completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05910827
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05910827-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT05910827)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Phase Ib/II Study of an Anti-HER3 Antibody\, HMBD-001\, With Cet
 uximab +/- Docetaxel in Advanced Squamous Cell Cancers\nEstimated primary 
 completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05910827
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063552-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Cetuximab: Phase 2/3 readout est. (NCT05063552)
DESCRIPTION:Cetuximab\, phase 2/3\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: Testing the Use of Investigational Drugs Atezolizumab and/or Bevac
 izumab With or Without Standard Chemotherapy in the Second-Line Treatment 
 of Advanced-Stage Head and Neck Cancers\nEstimated primary completion: 15 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuxi
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05063552
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063552-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Taxotere (Docetaxel): Phase 2/3 readout est. (NCT05063552)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2/3\, Head and Neck Squamous Cell 
 Carcinoma.\nStudy: Testing the Use of Investigational Drugs Atezolizumab a
 nd/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line
  Treatment of Advanced-Stage Head and Neck Cancers\nEstimated primary comp
 letion: 15 December 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/docetaxel#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05063552
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01154920-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT01154920)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Paclitaxel\, Carboplatin and Cetuximab (PCC) With Cetuximab\, Doceta
 xel\, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients 
 With Locally Advanced Head and Neck Squamous Cell Carcinoma\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT01154920
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01154920-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT01154920)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: Paclitaxel\, Carboplatin and Cetuximab (PCC) With Cetuxim
 ab\, Docetaxel\, Cisplatin and Fluorouracil (C-TPF) in Previously Untreate
 d Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma\nEs
 timated primary completion: 31 December 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT01154920
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618624-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07618624)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: BRIDGE Study: Neoadjuvant Finotonlimab\, Cetuximab\, and Docetaxel i
 n Resectable Recurrent HNSCC After Immunotherapy Progression\nEstimated pr
 imary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07618624
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07618624-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07618624)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: BRIDGE Study: Neoadjuvant Finotonlimab\, Cetuximab\, and 
 Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression\nE
 stimated primary completion: 31 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07618624
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05726370-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT05726370)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Preoperative Pembrolizumab and Chemotherapy in Resectable\, Recu
 rrent HNSCC\nEstimated primary completion: 31 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05726370
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06636734-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06636734)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Lovastatin and Pembrolizumab for the Treatment of Patients With 
 Recurrent or Metastatic Head and Neck Cancer\, LAPP Trial\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06636734
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05726370-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT05726370)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: Preoperative Pembrolizumab and Chemotherapy in Resectable
 \, Recurrent HNSCC\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05726370
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07214987-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07214987)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: PDT For Induction Therapy For Head And Neck Cancer\nEstim
 ated primary completion: 31 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07214987
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06725368-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06725368)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembroli
 zumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Ca
 rcinoma of the Head and Neck\nEstimated primary completion: January 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06725368
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06725368-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06725368)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pemb
 rolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cel
 l Carcinoma of the Head and Neck\nEstimated primary completion: January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0672536
 8
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07063212-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280102
DTEND;VALUE=DATE:20280103
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07063212)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: A Study of Sacituzumab Govitecan in Combination With Cetuximab in Pe
 ople With Head and Neck Squamous Cell Cancer (HNSCC)\nEstimated primary co
 mpletion: 2 January 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07063212
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06223568-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06223568)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or
  in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newl
 y Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer\nEstimated
  primary completion: 10 January 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06223568
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06940180-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT06940180)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: Toripalimab With Chemotherapy for Sinus Cancer\nEstimated
  primary completion: 1 February 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06940180
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747585-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06747585)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pe
 mbrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors\nEstimated
  primary completion: 15 February 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06747585
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06747585-2338@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:ALE.P02: Phase 1/2 readout est. (NCT06747585)
DESCRIPTION:ALE.P02\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Investigate ALE.P02 as a Monotherapy or in Combination With Pembroli
 zumab in Adult Patients With Selected CLDN1+ Solid Tumors\nEstimated prima
 ry completion: 15 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/ale-p02#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06747585
URL:https://assetmemo.bio/drug/ale-p02#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855212-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06855212)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients U
 ndergoing Surgery for HNSCC\nEstimated primary completion: March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06855212
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807163-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07807163)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination Wi
 th Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC\
 nEstimated primary completion: March 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07807163
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269381-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05269381)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrol
 izumab for Treatment of Advanced Solid Tumors\nEstimated primary completio
 n: 31 March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pem
 brolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05269381
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07465276-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07465276)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
 \nEstimated primary completion: 30 April 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07465276
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03526835-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT03526835)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid T
 umors\nEstimated primary completion: May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03526835
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07484139-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07484139)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembro
 lizumab (Keytruda) in Surgically Resectable\, HPV Negative Oral Cavity Squ
 amous Cell Carcinoma (OCSCC)\nEstimated primary completion: May 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07484139
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07254585-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07254585)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic He
 ad And Neck Squamous Cell Carcinoma\nEstimated primary completion: 30 June
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0725
 4585
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317000-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05317000)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC\nE
 stimated primary completion: 30 June 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05317000
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07254585-2211@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:CPO301: Phase 2 readout est. (NCT07254585)
DESCRIPTION:CPO301\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nStud
 y: SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And 
 Neck Squamous Cell Carcinoma\nEstimated primary completion: 30 June 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cpo301#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07254585
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06699212-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06699212)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study of ASP-1929 Photoimmunotherapy in Combination With Pembr
 olizumab in First-line Treatment of Locoregional Recurrent Squamous Cell C
 arcinoma of the Head and Neck With No Distant Metastases\nEstimated primar
 y completion: September 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06699212
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07758621-2211@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20280915
DTEND;VALUE=DATE:20280916
SUMMARY:CPO301: Phase 3 readout est. (NCT07758621)
DESCRIPTION:CPO301\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nStud
 y: SYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurr
 ent or Metastatic HNSCC\nEstimated primary completion: 15 September 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/cpo301#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07758621
URL:https://assetmemo.bio/drug/cpo301#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07062354-2020@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Amivantamab: Phase 2 readout est. (NCT07062354)
DESCRIPTION:Amivantamab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: Combined Amivantamab\, Carboplatin and Paclitaxel in Unresectable 
 Locally Recurrent or Metastatic Head and Neck Cancer\nEstimated primary co
 mpletion: October 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/amivantamab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07062354
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06856213-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06856213)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To
  First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Met
 astatic Squamous Cell Carcinoma of the Head and Neck.\nEstimated primary c
 ompletion: October 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06856213
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07882888-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Cetuximab: Phase 2 readout est. (NCT07882888)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Iparomlimab and Tuvonralimab With With Cetuximab in Resectable OSCC\
 nEstimated primary completion: 16 October 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07882888
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05086692-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20281020
DTEND;VALUE=DATE:20281021
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05086692)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  A Beta-only IL-2 ImmunoTherapY Study\nEstimated primary completion: 20 Oc
 tober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05086692
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07932067-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20281115
DTEND;VALUE=DATE:20281116
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07932067)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Circulating Tumor DNA-Informed Adjuvant Therapy for Intermediate
 -Risk Head and Neck Cancer\nEstimated primary completion: 15 November 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07932067
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06535607-1985@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Volrustomig: Phase 2 readout est. (NCT06535607)
DESCRIPTION:Volrustomig\, phase 2\, Cervical Cancer.\nStudy: Study of Volru
 stomig as Monotherapy or in Combination With Anti- Cancer Agents in Partic
 ipants With Advanced/Metastatic Solid Tumors\nEstimated primary completion
 : 30 November 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/v
 olrustomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06535607
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06137378-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06137378)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: European Larynx Organ Preservation Study (ELOS) [MK-3475-C44]\nE
 stimated primary completion: December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06137378
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06894459-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06894459)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Prospective\, Multicenter\, Multicohort Phase II Study: Evalua
 ting the Efficacy and Safety of Preoperative Neoadjuvant Treatment With a 
 PD-1 Inhibitor in Combination With Chemotherapy in Locally Advanced Laryng
 eal and Hypopharyngeal Squamous Cell Carcinoma\nEstimated primary completi
 on: 1 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06894459
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06935188-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT06935188)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Dalpicilib Plus Cetuximab Compared With Cetuximab Alone in HPV-negat
 ive\, Anti-PD-1-resistant R/M HNSCC\nEstimated primary completion: 31 Dece
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0693
 5188
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07552558-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT07552558)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Head and Neck Squamous Cell Carcino
 ma.\nStudy: Ficerafusp Alfa\, Pembrolizumab\, and Stereotactic Body Radiot
 herapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)\nEstimated
  primary completion: 31 January 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07552558
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06823479-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06823479)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Towards Cure Via Only Ultra-short ICB in CSCC\nEstimated primary com
 pletion: February 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06823479
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05721755-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT05721755)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Combining Radiation Therapy With Immunotherapy for the Treatment
  of Metastatic Squamous Cell Carcinoma of the Head and Neck\nEstimated pri
 mary completion: 31 March 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05721755
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276399-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20290618
DTEND;VALUE=DATE:20290619
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07276399)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study of Amivantamab in Addition to Standard of Care Agents (S
 OC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head
  and Neck Cancer\nEstimated primary completion: 18 June 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07276399
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276399-2020@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20290618
DTEND;VALUE=DATE:20290619
SUMMARY:Amivantamab: Phase 3 readout est. (NCT07276399)
DESCRIPTION:Amivantamab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Study of Amivantamab in Addition to Standard of Care Agents (SOC
 ) Compared With SOC Alone in Participants With Recurrent/Metastatic Head a
 nd Neck Cancer\nEstimated primary completion: 18 June 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/amivantamab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07276399
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04671667-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT04671667)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Testing What Happens When an Immunotherapy Drug (Pembrolizumab) 
 is Given by Itself Compared to the Usual Treatment of Chemotherapy With Ra
 diation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma\
 nEstimated primary completion: 30 June 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04671667
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07065630-1985@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20290813
DTEND;VALUE=DATE:20290814
SUMMARY:Volrustomig: Phase 2 readout est. (NCT07065630)
DESCRIPTION:Volrustomig\, phase 2\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: Response-Adaptive Treatment in Untreated Locoregional HPV-Negative
  Head and Neck Cancer\nEstimated primary completion: 13 August 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/volrustomig#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07065630
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Q
 UILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Pr
 eviously Received Treatment With Immune Checkpoint Inhibitors\nEstimated p
 rimary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUILT
 -3.055: A Study of Combination Immunotherapies in Patients Who Have Previo
 usly Received Treatment With Immune Checkpoint Inhibitors\nEstimated prima
 ry completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT03228667)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Non-Small Cell Lung Cancer.\nS
 tudy: QUILT-3.055: A Study of Combination Immunotherapies in Patients Who 
 Have Previously Received Treatment With Immune Checkpoint Inhibitors\nEsti
 mated primary completion: 31 August 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576725-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07576725)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Low D
 ose\, Reduced Frequency Nivolumab for the Treatment of Unresectable or Met
 astatic Cancer\, AFFORD IO Trial\nEstimated primary completion: 31 August 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07576725
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07888816-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07888816)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Optimizing Response to Immunotherapy With Online Adaptive Pulsed
  Radiotherapy in Incurable Head and Neck Cancers\nEstimated primary comple
 tion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07888816
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06647563-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Cetuximab: Phase 3 readout est. (NCT06647563)
DESCRIPTION:Cetuximab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Neoadjuvant Toripalimab + Chemotherapy ± Cetuximab in Locally Advan
 ced Head and Neck Squamous Cell Carcinoma (Neo-ICT)\nEstimated primary com
 pletion: 30 September 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/cetuximab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06647563
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744126-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07744126)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study to Assess Adverse Events\, Change in Disease Activity an
 d Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembro
 lizumab for First-Line Treatment of Adult Participants With Recurrent or M
 etastatic Head and Neck Squamous Cell Carcinoma\nEstimated primary complet
 ion: October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pe
 mbrolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07744126
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07773987-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07773987)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Immunotherapy and Nodal-Sparing Irradiation for T-Cell Induction
  and Unmasking of Tumor Antigenicity in the Microenvironment for Head and 
 Neck Cancer\nEstimated primary completion: October 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07773987
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187338-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT05187338)
DESCRIPTION:Pembrolizumab\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors\n
 Estimated primary completion: 30 October 2029. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05187338
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07732634-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07732634)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Phase 2 Study of RiMO-301 for the Neoadjuvant Treatment of Resec
 table\, Locally Advanced Head-Neck Cancer\nEstimated primary completion: N
 ovember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrol
 izumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07732634
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06295731-2546@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ordastobart: Phase 2/3 readout est. (NCT06295731)
DESCRIPTION:Ordastobart\, phase 2/3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1
 + R/M OPSCC (HexAgon-HN)\nEstimated primary completion: December 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ordastobart#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06295731
URL:https://assetmemo.bio/drug/ordastobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05226871-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Cetuximab: Phase 2 readout est. (NCT05226871)
DESCRIPTION:Cetuximab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Study for Participants Continuing From Pfizer-sponsored Palbociclib 
 (a Study Medicine) Studies\nEstimated primary completion: 31 December 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05226871
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07354984-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Taxotere (Docetaxel): Phase 2 readout est. (NCT07354984)
DESCRIPTION:Taxotere (Docetaxel)\, phase 2\, Head and Neck Squamous Cell Ca
 rcinoma.\nStudy: A Single-Arm Phase II Clinical Study of Docetaxel Combine
 d With Nimotuzumab and Pucotenlimab as Second-Line and Beyond Therapy for 
 Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma\nEstimated prim
 ary completion: 31 December 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/docetaxel#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07354984
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06129864-1985@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20300417
DTEND;VALUE=DATE:20300418
SUMMARY:Volrustomig: Phase 3 readout est. (NCT06129864)
DESCRIPTION:Volrustomig\, phase 3\, Head and Neck Squamous Cell Carcinoma.\
 nStudy: A Global Study of Volrustomig (MEDI5752) for Participants With Unr
 esected Locally Advanced Head and Neck Squamous Cell Carcinoma Following D
 efinitive Concurrent Chemoradiotherapy\nEstimated primary completion: 17 A
 pril 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/volrustomi
 g#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 129864
URL:https://assetmemo.bio/drug/volrustomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07485296-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07485296)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Effect of Postbiotics on Microbiota and Systemic Immunomodulatio
 n of Pembrolizumab as First-Line Therapy in Recurrent/Metastatic Head and 
 Neck Squamous Cell Carcinoma (RM HNSCC)\nEstimated primary completion: Dec
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembroliz
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07485296
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432087-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Cetuximab: Phase 3 readout est. (NCT07432087)
DESCRIPTION:Cetuximab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy 
 for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cel
 l Carcinoma\nEstimated primary completion: 31 December 2030. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07432087
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07172256-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07172256)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs\nEstim
 ated primary completion: February 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07172256
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of BMS-986340 as Monotherapy and as Combination Therapy in Participan
 ts With Advanced Solid Tumors\nEstimated primary completion: 31 August 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04895709
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Non-Small Cell Lung Cancer.\
 nStudy: A Study of BMS-986340 as Monotherapy and as Combination Therapy in
  Participants With Advanced Solid Tumors\nEstimated primary completion: 31
  August 2031. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/docetax
 el#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4895709
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509099-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Cetuximab: Phase 3 readout est. (NCT07509099)
DESCRIPTION:Cetuximab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemothera
 py in R/M HNSCC\nEstimated primary completion: 30 September 2031. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07509099
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509099-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07509099)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemot
 herapy in R/M HNSCC\nEstimated primary completion: 30 September 2031. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07509099
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07026474-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20321231
DTEND;VALUE=DATE:20330101
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT07026474)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy 
 for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC\nEstimated pri
 mary completion: December 2032. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07026474
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06589804-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20321225
DTEND;VALUE=DATE:20321226
SUMMARY:Cetuximab: Phase 3 readout est. (NCT06589804)
DESCRIPTION:Cetuximab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Testing the Addition of Anti-Cancer Drug\, Cetuximab\, to Standard o
 f Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck 
 Cancer After Previous Treatment\nEstimated primary completion: 25 December
  2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/cetuximab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06589804
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06589804-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20321225
DTEND;VALUE=DATE:20321226
SUMMARY:Pembrolizumab: Phase 3 readout est. (NCT06589804)
DESCRIPTION:Pembrolizumab\, phase 3\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Testing the Addition of Anti-Cancer Drug\, Cetuximab\, to Standa
 rd of Care Treatment (Pembrolizumab) for Returning or Spreading Head and N
 eck Cancer After Previous Treatment\nEstimated primary completion: 25 Dece
 mber 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pembrolizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06589804
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385080-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20321227
DTEND;VALUE=DATE:20321228
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT06385080)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Head and Neck Squamous Cell Carcino
 ma.\nStudy: A Study of Amivantamab Alone or in Addition to Other Treatment
  Agents in Participants With Head and Neck Cancer\nEstimated primary compl
 etion: 27 December 2032. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06385080
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385080-2020@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20321227
DTEND;VALUE=DATE:20321228
SUMMARY:Amivantamab: Phase 1/2 readout est. (NCT06385080)
DESCRIPTION:Amivantamab\, phase 1/2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: A Study of Amivantamab Alone or in Addition to Other Treatment A
 gents in Participants With Head and Neck Cancer\nEstimated primary complet
 ion: 27 December 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/amivantamab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06385080
URL:https://assetmemo.bio/drug/amivantamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06557889-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20330430
DTEND;VALUE=DATE:20330501
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT06557889)
DESCRIPTION:Pembrolizumab\, phase 2\, Head and Neck Squamous Cell Carcinoma
 .\nStudy: Reduction in the Number of Chemotherapy Cycles in Combination Wi
 th Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Me
 tastatic Head and Neck Squamous Cell Carcinomas\nEstimated primary complet
 ion: April 2033. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pemb
 rolizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06557889
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Pembrolizumab: Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Pembrolizumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy:
  Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytr
 uda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexav
 alent OX40 Agonist)\nEstimated primary completion: July 2033. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/pembrolizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04198766-2546@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20330731
DTEND;VALUE=DATE:20330801
SUMMARY:Ordastobart: Phase 1/2 readout est. (NCT04198766)
DESCRIPTION:Ordastobart\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytrud
 a®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexaval
 ent OX40 Agonist)\nEstimated primary completion: July 2033. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ordastobart#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04198766
URL:https://assetmemo.bio/drug/ordastobart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03755739-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20331101
DTEND;VALUE=DATE:20331102
SUMMARY:Pembrolizumab: Phase 2/3 readout est. (NCT03755739)
DESCRIPTION:Pembrolizumab\, phase 2/3\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus C
 hemodrug for Immunotherapy of Advanced Solid Tumors\nEstimated primary com
 pletion: 1 November 2033. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03755739
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07441681-1965@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20351130
DTEND;VALUE=DATE:20351201
SUMMARY:Cetuximab: Phase 3 readout est. (NCT07441681)
DESCRIPTION:Cetuximab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in
  People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin\nE
 stimated primary completion: 30 November 2035. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/cetuximab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07441681
URL:https://assetmemo.bio/drug/cetuximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667400-9029@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20361001
DTEND;VALUE=DATE:20361002
SUMMARY:Taxotere (Docetaxel): Phase 1/2 readout est. (NCT07667400)
DESCRIPTION:Taxotere (Docetaxel)\, phase 1/2\, Metastatic Castration-Resist
 ant Prostate Cancer.\nStudy: Docetaxel and SX-682 in Recurrent/Metastatic 
 Head and Neck Squamous Cell Carcinoma\, Salivary Gland Carcinoma\, and Adv
 anced Prostate Cancer\nEstimated primary completion: 1 October 2036. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/docetaxel#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07667400
URL:https://assetmemo.bio/drug/docetaxel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770100-1973@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20400228
DTEND;VALUE=DATE:20400229
SUMMARY:Pembrolizumab: Phase 2 readout est. (NCT07770100)
DESCRIPTION:Pembrolizumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: C
 oncurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiat
 ion Therapy (SBRT) for Stage IV Cancers (COINSSS IV)\nEstimated primary co
 mpletion: 28 February 2040. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pembrolizumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07770100
URL:https://assetmemo.bio/drug/pembrolizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770100-1974@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20400228
DTEND;VALUE=DATE:20400229
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07770100)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Concu
 rrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation 
 Therapy (SBRT) for Stage IV Cancers (COINSSS IV)\nEstimated primary comple
 tion: 28 February 2040. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07770100
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
